CVE-2026-32235 - @backstage/plugin-auth-backend: OAuth redirect URI allowlist bypass
CVE ID :CVE-2026-32235
Published : March 12, 2026, 7:16 p.m. | 2 hours, 13 minutes ago
Description :Backstage is an open framework for building developer portals. Prior to 0.27.1, the experimental OIDC provider in @backstage/plugin-auth-backend is vulnerable to a redirect URI allowlist bypass. Instances that have enabled experimental Dynamic Client Registration or Client ID Metadata Documents and configured allowedRedirectUriPatterns are affected. A specially crafted redirect URI can pass the allowlist validation while resolving to an attacker-controlled host. If a victim approves the resulting OAuth consent request, their authorization code is sent to the attacker, who can exchange it for a valid access token. This requires victim interaction and that one of the experimental features is explicitly enabled, which is not the default. This vulnerability is fixed in 0.27.1.
Severity: 5.9 | MEDIUM
Visit the link for more details, such as CVSS details, affected products, timeline, and more...
Published : March 12, 2026, 7:16 p.m. | 2 hours, 13 minutes ago
Description :Backstage is an open framework for building developer portals. Prior to 0.27.1, the experimental OIDC provider in @backstage/plugin-auth-backend is vulnerable to a redirect URI allowlist bypass. Instances that have enabled experimental Dynamic Client Registration or Client ID Metadata Documents and configured allowedRedirectUriPatterns are affected. A specially crafted redirect URI can pass the allowlist validation while resolving to an attacker-controlled host. If a victim approves the resulting OAuth consent request, their authorization code is sent to the attacker, who can exchange it for a valid access token. This requires victim interaction and that one of the experimental features is explicitly enabled, which is not the default. This vulnerability is fixed in 0.27.1.
Severity: 5.9 | MEDIUM
Visit the link for more details, such as CVSS details, affected products, timeline, and more...